{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:43:59Z","timestamp":1794829439502,"version":"4.9.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n                           <jats:sup>68<\/jats:sup>Ga-labeled PET tracer targeting PSMA is a promising diagnostic approach for staging and restating of prostate cancer (PCa), but cases with clinically relevant PCa and false-negative PSMA PET\/CT have been reported. In this case, we reported <jats:sup>68<\/jats:sup>Ga-PSMA, <jats:sup>18<\/jats:sup>F-FDG, and <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT findings in a 65-year-old man with de novo metastatic PCa. <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT detected non\u2013PSMA\/FDG-avid primary PCa, consisting with multiparametric MRI findings. The subsequent histopathologic examination confirmed a Gleason 4 + 5 PCa. This case highlighted that <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT may be a useful imaging modality for primary PCa detection and localization.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004349","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:09Z","timestamp":1660348809000},"page":"1108-1111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["68Ga-FAPI PET\/CT Detected Non\u2013PSMA\/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer"],"prefix":"10.1097","volume":"47","author":[{"given":"Yizhen","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","article-title":"Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","article-title":"Fibroblast activation protein-targeted PET imaging of metastatic castration-resistant prostate cancer compared with 68Ga-PSMA and 18F-FDG PET\/CT","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/RLU.0000000000001419","article-title":"68Ga-DOTATOC and 68Ga-PSMA PET\/CT unmasked a case of prostate cancer with neuroendocrine differentiation","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000001618","article-title":"Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.119.228320","article-title":"Multimodality imaging of prostate cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:40Z","timestamp":1750536340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004349","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}